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Bursa Uludağ University Faculty of Medicine, Görükle Campus, Nilüfer 16059, Bursa, Turkey
Correspondence: dr.arifhussain@yahoo.co.in (A.H.); shafiul.haque@hotmail.com (S.H.);
reshisalim@gmail.com (M.S.R.)

Qadri, S.S.; Pramodh, S.; Alsulimani,
A.; Alkhanani, M.F.; Harakeh, S.; et al.
Oxidative Stress in Human Pathology
and Aging: Molecular Mechanisms
and Perspectives. Cells 2022, 11, 552.
https://doi.org/10.3390/
cells11030552
Academic Editors: Carsten Theiss
and Veronika Matschke
Received: 13 November 2021
Accepted: 24 January 2022
Published: 5 February 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affiliations.

Abstract: Reactive oxygen and nitrogen species (RONS) are generated through various endogenous
and exogenous processes; however, they are neutralized by enzymatic and non-enzymatic antioxidants. An imbalance between the generation and neutralization of oxidants results in the progression
to oxidative stress (OS), which in turn gives rise to various diseases, disorders and aging. The characteristics of aging include the progressive loss of function in tissues and organs. The theory of aging
explains that age-related functional losses are due to accumulation of reactive oxygen species (ROS),
their subsequent damages and tissue deformities. Moreover, the diseases and disorders caused by
OS include cardiovascular diseases [CVDs], chronic obstructive pulmonary disease, chronic kidney
disease, neurodegenerative diseases and cancer. OS, induced by ROS, is neutralized by different
enzymatic and non-enzymatic antioxidants and prevents cells, tissues and organs from damage.
However, prolonged OS decreases the content of antioxidant status of cells by reducing the activities
of reductants and antioxidative enzymes and gives rise to different pathological conditions. Therefore,
the aim of the present review is to discuss the mechanism of ROS-induced OS signaling and their
age-associated complications mediated through their toxic manifestations in order to devise effective
preventive and curative natural therapeutic remedies.
Keywords: oxidative stress; reactive oxygen species; pathologies; mechanisms; aging
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1. Introduction
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The foremost evolutionary outcome following various metabolic changes is the ability
to bind energy in the form of adenosine triphosphate (ATP). Enzymes involved in various
metabolic pathways produce energy through different biochemical reactions that prompt
the final reduction in molecular oxygen (O2 ). Different processes of amphibolic metabolic

conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

Cells 2022, 11, 552. https://doi.org/10.3390/cells11030552

https://www.mdpi.com/journal/cells

Cells 2022, 11, 552

2 of 27

pathways such as the tricarboxylic acid (TCA) cycle and the respiratory chain are linked to
the inner mitochondrial membrane, which produces reactive oxygen species (ROS) and
generates free radicals. The generation of free radicals is a basic and useful incident for
the proper functioning, protection and survival of cells within physiological limits [1–3].
However, an imbalance in the generation and neutralization of ROS may lead to the accumulation of ROS intermediate products which are thought to be detrimental and may
induce oxidative stress (OS) [1,4,5]. ROS are essential for maintenance of homeostatic
environment for the cell survival, because they play a significant physiological role in
defense mechanisms [6]. Therefore, ROS are important for the survival as well as adaptation, for instance, hydrogen peroxide and superoxide anion are substantial factors which
are involved in the developmental signaling transduction in the pancreatic β-cells having
ability to control insulin secretion [7–9]. However, the concentration of ROS may increase
rapidly and reach toxic levels after calcium ion stimulation of the TCA cycle, an increase in
the activity of respiratory chains, the transport of electrons and the activity of NADPH [10].
Furthermore, oxidative stress may be increased in the cell or tissue if there will be elevation
in the rate of production and alleviation in the rate of neutralization of ROS [11]. Prolonged
higher OS leads to various life-threatening pathological conditions such as aging, heart diseases, diabetes, autoimmune diseases, cancer, neurological disorders, etc. [12]. Elucidating
the underlying mechanisms of OS-induced pathogenesis of numerous clinical conditions
and aging will help in the development of therapeutic agents against such diseases and
disorders for the overall well-being of humans.
1.1. Mechanism of ROS
Mitochondria are the primary endogenous source for ROS production due to their
role in the ATP production via oxidative phosphorylation, during which the molecular O2
becomes reduced into H2 O in electron transport chain (ETC). Mitochondrial superoxide
production is an important source of ROS in cells. Seven major sites of superoxide production are recognized in mammalian mitochondria. In a descending order of maximum
capacity, they are the ubiquinone binding sites in complex I (site IQ) and complex III (site
IIIQo), glycerol 3-phosphate dehydrogenase (GPDH.), the flavin in complex I (site IF), the
electron transferring flavor protein: Q oxidoreductase (ETFQOR) of fatty acid beta oxidation, and pyruvate and 2-oxoglutarate dehydrogenases. [13]. All these complexes release
O− 2 in the mitochondrial matrix except complex III site and GPDH. In the mitochondrial
membrane, superoxide dismutase is present in three forms viz. manganese superoxide
dismutase (Mn-SOD), copper superoxide dismutase and zinc superoxide dismutase. Manganese superoxide dismutase (Mn-SOD) converts O− 2 into hydrogen peroxide (H2 O2 ) and
then aconitase enzyme converts H2 O2 to a hydroxyl radical via Fenton reaction [14], while
copper superoxide dismutase and zinc superoxide dismutase change O− 2 into the inter
membrane space [15].
Another route of ROS generation is mitochondrial cytochrome catalytic cycle, it comprises Cytochrome P450 enzyme consisting of wide spectrum of organic compounds, such
as lipids, steroids, and xenobiotics. It produces various reactive byproducts such as superoxide radical and H2 O2 [16,17]. Moreover, in mammals, a range of protein complexes
also produce ROS, such as Nicotinamide adenine dinucleotide (NADH)-cytochrome b5 reductase (b5R) [18], dihydroorotate dehydrogenase (DHODH) [19,20], complex II: succinate
dehydrogenase (SDH) [21,22], and monoamine oxidases (MAO) [23]. Several defense
systems, in the form of antioxidants like GPXs, TRXPs, SODs, PRDXs, GSH, TRX2, GRX2,
cyt c oxidase (complex IV), coenzyme Q, ascorbic acid, vitamin E and carotenes, protect the
mitochondria from detrimental effects of ROS [23–26]. However, overproduction of ROS is
associated with different pathologies in human beings such as mitochondrial dysfunction,
cancer, inflammation, neurological and neurodegenerative diseases, diabetes, chronic renal
diseases, aging and DNA damage [27–30]. Genomic DNA and/or mitochondrial DNA
damage, mutations in somatic cells, instability in genome, oncogene activation, inhibition
of tumor suppressor genes, changes in various pathways of metabolism and signaling
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1.3. ROS as Second Messengers
ROS can act as second messengers in some situations, and their optimum concentrations activate a variety of signal transduction pathways in the cell and facilitate the actions
of growth factors like cytokines, and Ca2+ signaling. Furthermore, the role of ROS can be
explained through the c-Jun N-terminal kinases (JNKs), a member of protein kinase family
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which is activated by ROS through the production of lipid peroxide intermediates and then
phosphorylated. Following its phosphorylation, it releases two B-cell lymphoma 2-related
proteins (BCL2) and sequestered in the cell [36,37]. After the release of these proteins, they
directly activate theBCL2-associated X (Bax) proteins through cytoplasmic anchor.
Hydrogen peroxide (H2 O2 ) is an essential metabolite involved in various redox
metabolic reactions and cellular processes. It has been identified that H2 O2 acts as a
sensor, modulator and signaling molecule during redox metabolism, and also works as
a second messenger along with hydrogen sulfide (H2 S) and nitric oxide (NO) [38–40].
Following the activation of these second messengers, they activate a downstream protein
cascade through specific oxidations, thus leading to the cellular metabolic response [41–43].
This metabolic response can influence proliferation, survival or death of the cell depending
on which downstream pathways (homeostatic, pathological or protective) have been activated [44]. In cells, H2 O2 is produced from various sources such as either a spontaneous or
catalytic breakdown of superoxide anion, produced through the partial reduction of oxygen
during aerobic respiration or through various oxidases, and is quickly converted into H2 O2
by superoxide dismutase present in the mitochondria or cytosol or in the extracellular
space [45–47] and regulatory machinery of the cell maintains the concentration in different
sub-cellular compartments.
In biological systems and in medicine, H2 O2 is used as anti-infective agent, such as for
the cleaning of wounds, due to its strong oxidative potential to kill microorganisms and
cells [38,48]. Hydrogen peroxide contributes to the maintenance of homeostatic metabolism,
because it is a key molecule in the Third Principle of the Redox Code “Redox sensing
by activating/deactivating cyclic production associated with NAD and NADP system
to support spatiotemporal organization of key processes” [49–51] of living organisms
and contributes to the regulation of cellular metabolism. H2 O2 diffuses through the cell
membrane through aquaporin water channels (AQP) transducing the redox signal from the
place where it is produced to a target site [52]. H2 O2 activates various transcription factors
in bacteria, lower eukaryotes and mammalian cells [53] and this stimulation finally leads to
a metabolic response of the cell to the original stimuli [54].
1.4. ROS Induces Multifaceted Alterations
An imbalance between free radicals and oxidants gives rise a tense-full situation in
the living system known as oxidative stress. Oxidative stress is a harmful process because
it adversely affects the structure of cell membranes, lipids, proteins, lipoproteins and
deoxyribonucleic acid (DNA) [55–61]. Likewise, the excessive production of hydroxyl
radicals and peroxynitrile leads to peroxidation of lipids; hence, this damages the cellular
membrane and lipoproteins. This in turn results in the formation of malondialdehyde
(MDA) and conjugated diene compounds; both of these are known as cytotoxic and
mutagenic compound. The rate of lipid peroxidation increases very rapidly and affects
a huge quantity of lipidic molecules [62]. Due to peroxidative damage, proteins are also
affected by OS, undergoing structural modifications that may indicate loss or an impairment
of their respective enzymatic activity [59,63].
Prolonged OS causes lesions in DNA; the most common base affected is guanine bases
in DNA and form 8-hydroxydeoxyguanosine (8-OHdG), which can bind to thymidine
rather than cytosine. The level of 8-OHdG is generally considered to be a pernicious DNA
lesion and is responsible for the mutagenesis [64]. Oxidative DNA damage can lead to
the loss of epigenetic information, possibly due to the damage in CpG island methylation
asset in promotor regions of a gene [65]. Moreover, it has been studied that 8-OHdG acts a
tissue biomarker of oxidative stress. Therefore, considering all these consequences, it can
infer that OS may induce various diseases (acute and chronic) speedup ageing processes
of cells and also causes acute pathologies (trauma and stroke). Prolonged and higher OS
leads to various life-threatening pathological conditions such as cardiovascular disease [66],
respiratory diseases [67,68], rheumatoid arthritis [69], neurological disorders [70], liver
and kidney diseases, reproductive diseases and diabetes [71,72]. Oxidative stress initiates

Cells 2022, 11, 552

loss of epigenetic information, possibly due to the damage in CpG island methylation asset in promotor regions of a gene [65]. Moreover, it has been studied that 8-OHdG acts a
tissue biomarker of oxidative stress. Therefore, considering all these consequences, it can
infer that OS may induce various diseases (acute and chronic) speedup ageing processes
of cells and also causes acute pathologies (trauma and stroke). Prolonged and higher OS
5 of 27
leads to various life-threatening pathological conditions such as cardiovascular disease
[66], respiratory diseases [67,68], rheumatoid arthritis [69], neurological disorders [70],
liver and kidney diseases, reproductive diseases and diabetes [71,72]. Oxidative stress initiates various
apoptotic
signaling
pathways
to increased
production
or revarious
apoptotic
signaling
pathways
due to due
increased
production
of ROSoforROS
reduction
duction
in
the
activities
antioxidative
enzymes,
disruption
of
intracellular
redox
homeoin the activities antioxidative enzymes, disruption of intracellular redox homeostasis and
stasis and peroxidative
in lipids,orproteins
or fragmentation
of DNA. ROS-mediperoxidative
damage indamage
lipids, proteins
fragmentation
of DNA. ROS-mediated
toxic
ated toxic manifestations
been in
explained
manifestations
have been have
explained
Figure 2.in Figure 2.

Figure
Figure 2.
2. ROS-mediated
ROS-mediated toxic
toxic manifestations
manifestations such
such as
as ROS-mediated
ROS-mediated DNA
DNA damage;
damage; peroxidative
peroxidative
damage
degradation
of proteins
caused
ROS,ROS,
Base Base
modifications
of Bases,
damage of
ofmembrane
membranelipids,
lipids,
degradation
of proteins
caused
modifications
of where
Bases,
MDA:
TBARS:TBARS:
Thiobarbituric
acid-reactive
species,species,
*, unpaired
electron.
where Malondialdehyde,
MDA: Malondialdehyde,
Thiobarbituric
acid-reactive
*, unpaired
electron.

1.5. Physiological Impacts of ROS
Reactive oxygen species (ROS) protect the body from pathogens such as microbes
and foreign agents. At a physiological level, ROS destroy pathogens; hence, they act as an
immune system to provide defense against foreign bodies [73], and are also used for the
formation
such
as protein
complexes
[74]. [74].
Cells Cells
may produce
ROS exogeformation of
ofcell
cellstructures
structures
such
as protein
complexes
may produce
ROS
nously and they are used for intracellular signaling and also for exciting redox-sensitive
signaling pathways because ROS increase the production of cytoprotective regulatory
proteins [1,75]. Therefore, ROS control pro-inflammatory signaling, pro-fibrotic signaling,
the proliferation of cells, cell death and a variety of other biological processes without
activating a necessity for macromolecular damage [76,77].
The redox state of sulfur switches comprises three central proteins complexes such as
Cys/CySS, GSH/GSSG and thioredoxins (Trx) that maintains the equilibrium values of
redox protein complexes in cellular organelles [78,79]. For the maintenance of the structure
of proteins, trafficking of protein, enzyme regulation, signaling of cells and receptors,
various transcription factors sulfur switches are used widely [80]. An imbalance in the ROS
system in favor of surplus production of oxidants like hydroxyl ions might cause damage
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to the macromolecules, because the primary target of ROS including hydrogen peroxide
(a mild oxidant) is the –SH group of the Cys residues of the protein [81,82]. However,
thioredoxin and peroxiredoxin are able to reduce disulfide bonds and protein sulfenic acids
and act as mediators in redox signaling [83].
An accumulation in the ROS levels inside the cells leads to Cys oxidation residues in
intermembrane proteins such as kinases and phophatases due their contact with various
stimuli, eventually affecting the signal transduction processes [84]. The oxidized species
affect the growth factors, cytokines and hormones, or can induce the downregulatory effect
to signaling pathways such as PKa, mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) cascades [75]. Oxidants also inhibit the activity of phosphatases
via the oxidation of the reactive cys residue and inhibit its catalytic activity [85].
2. Effect of ROS on Human Health
The imbalance between the production and the elimination of free radicals leads to
OS inside the human body, which indicates that the level of oxidants overpowers the
antioxidant system and then these oxidants negatively affect the various cellular structures,
including membranes, proteins, lipids and DNA [1,86–90]. A well-known biomarker for
the assessment of (OS) is lipid peroxidation (LPO). The rate of LPO increases rapidly during
OS due to the peroxidative damage caused by free radicals on the polyunsaturated lipid
membrane. Moreover, OS also cause conformational changes in proteins, thus decreasing
their functional efficiency and alter their enzyme activities [89].
DNA damage and mutations induced by OS are associated with different human
pathologies including cancer. OS induces lesions in DNA, which reveals that ROS-induced
OS could lead to gene and chromosome mutations through DNA double-strand breaks
(DSBs) [91,92]. It has been reported that OS-induced DNA damage leads to the increased
production of mutagenic base8-oxo-20 -deoxyguanosine levels in a tissue which acts as a
biomarker for OS [93].
ROS-induced OS causes alterations in different organ systems, which are explained
as follows:
1.

2.

3.

ROS-induced neurotoxicity causes modulation in the neurons such as permeabilization of the cellular membrane, a decrease in the excitability property of neuronal
membrane and the activation of the KATP pump (Figure 3).
ROS-induced oxidative stress also leads to cardiac myopathy due to the mitochondrial
damage, perforations in the mitochondria, the release of Cytochrome C and the
initiation of apoptotic cascade (Figure 3).
Liver and kidneys are the primary targets for ROS attack due to their direct involvement in metabolic and filtration processes. In the liver, ROS induce damages to the
hepatocyte membranes and leads to deuteriation, which in turn leads to the deposition
of collagen in the hepatocyte and finally cause liver fibrosis and cirrhosis. In addition,
the incomplete oxidation of biomolecules causes lipoapoptosis in hepatic cells and induces immune reactions in the liver (Figure 3). In the kidneys, ROS-induced oxidative
stress mainly initiates the production of various pro-inflammatory cytokines, which
initiates nephrotic inflammation and finally affects the renal functions (Figure 3).
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tion (Figure 4). All these processes result in mitochondrial apoptosis and hamper ATP
production [100–104]. Some studies have reported that insulin secretion might be hampered due to overexpression of uncoupling protein 2 (negative controller of insulin secretion) in the mitochondria of pancreatic β-cells, which leads to a decline in the generation
of ATP and glucose-stimulated insulin secretion [105,106].
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Hyperglycemic conditions during diabetes cause various complications such as
hyperglycemia-induced autoxidation, resulting in the production of H2 O2 and ·OH which
affect the synthesis of insulin by damaging the insulin-mRNA, and finally decrease the
content of insulin and also reduce the functional efficacy of the insulin response (Figure 4).
Moreover, autoxidized glycolytic intermediates increase the production rate of glycation
end product, initiate various pathways, such as the protein kinase C pathway, hexosamine
pathway and the polyol pathway (Figure 4). The downregulatory end products of all
these pathways ultimately lead to microvascular complications due to the accumulation of
collagen fibronectin and protein glycation products (Figure 4).

Cells 2022, 11, x

Cells 2022, 11, 552

9 of 28

9 of 27
triggers pulsatile insulin secretion. Note: Upward arrows indicate increase and downward arrows
indicate decrease.
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2.3. Role of ROS in Cardiac Hypertrophy
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Cardiac hypertrophy (CH) is an adaptive response of the heart to pressure overload. It
is a general pathological characteristic in the natural course of some major cardiovascular
diseases, such as hypertension and myocardial infarction. Cardiac hypertrophy is strongly
associated with a higher risk for heart failure and sudden cardiac death. OS is considered
as one of the important contributing factors in the development of cardiac hypertrophy.
Different pathways are involved in the development of hypertrophy like Angiotensin-II
(Ang II)-induced cardiac hypertrophy which is induced by an extracellular signal. ROS
also activate a broad variety of hypertrophy signaling kinases and transcription factors,
such as MAP kinase, NF-κB, etc. In addition to the profound alteration of cellular function,
ROS modulate the extracellular matrix function, evidenced by increased interstitial and
perivascular fibrosis. AngII stimulates the expression of the hypertrophic factor, betamyosin heavy chain genes in myocytes, and is mediated via ROS-dependent activation
of the extracellular-signal-regulated kinase signaling cascades [110]. A study was conducted
on guinea pigs to evaluate progressive left ventricular hypertrophy, and it has been found
that the expression of p22phox , p67phox , p47phox , Nox2 and Nox activity was upregulated
during the progression of cardiac hypertrophy to failure [111]. Additionally, Nox can be
stimulated by angiotensin-II to generate ROS, causing the activation of p38MAP kinase
following AP-1 activation, while it has also been confirmed that the activation of Rac1 is a
critical step in hypertrophy progression [112]. Moreover, NADPH oxidase also increases
the production of ROS, which further accelerates these pathways. ET-1 causes hydrolysis
of phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3 and DAG, both these secondary
messengers activate calcium channels in the ER and releases Ca from it. Both Ca and KMUP1 activate the calcineurin, and it in turn actives NFATc4; finally, it increases AP-1 DNA
binding activity and initiates cardiac hypertrophy. ROS activation also activates HIF1-α,
cMyc, FOXO1 and PDK, and finally causes the activation of hypertrophic remodeling [113].
ROS also causes damage to the mitochondria, and cytochrome C is released from the
of 28
mitochondria, which finally leads to apoptosis [114–116]. All of these processes 11
collectively
result in cardiac hypertrophy (Figure 6)
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of PIP3 into IP3 and DAG, both of these activates the calcium channels and releases calcium from
endoplasmic reticulum. Liberation of Ca from ER inhibits the activation of Calcineurin, also mediated by KMUP-1, and finally causes cardiac hypertrophy through the activation of AP-1DNA binding activity of NFATc4. Moreover, ROS activates HIFI-1, FOXO-α and Myc pathways and leads to
the activation of hypertrophic remodeling. ROS also induce cardiac hypertrophy through the opening of mPTP channel, release of cytochrome C and induction of apoptosis of myocardial muscles.
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into IP3 and DAG, both of these activates the calcium channels and releases calcium from endoplasmic reticulum. Liberation of Ca from ER inhibits the activation of Calcineurin, also mediated by
KMUP-1, and finally causes cardiac hypertrophy through the activation of AP-1DNA binding activity
of NFATc4. Moreover, ROS activates HIFI-1, FOXO-α and Myc pathways and leads to the activation
of hypertrophic remodeling. ROS also induce cardiac hypertrophy through the opening of mPTP
channel, release of cytochrome C and induction of apoptosis of myocardial muscles. Additionally,
ROS induces inhibition of P13K, Akt and GSK-3β. All these pathways induce cardiac hypertrophy,
where ET-1: Endothelin-1, mPTP: Mitochondrial Permeability Transition Pore, ASK-1: Apoptosis
signal-regulating kinase-1, MMP. TIMP: Matrix metalloproteinase/Tissue inhibitors of metalloproteinases, AP-1: Activator protein 1, NF-κβ: Nuclear factor-κ Beta, KATP; ATP-sensitive potassium,
NADPH oxidase: Nicotinamide dinucleotide phosphate reduced, p38MAPK; p38 mitogen-activated
protein kinases, HIFA-α; Hypoxia-inducible factor 1-alpha, FOXO1; Fork-head box transcription
factors, PDK: Protein 3-phosphoinositide-dependent protein kinase, NLRP: Nucleotide-binding
oligomerization domain, MCP: Monocyte Chemo-attractant Protein, TNF-α:Tumor necrosis factor
alpha, IL-1β: Interleukin-1 beta.

3. Oxidative Stress and Neurodegenerative Diseases
3.1. Alzheimer’s Disease
Neurodegenerative diseases impact not only the life quality of aging populations,
but also their life spans. All forms of neurodegenerative diseases have a wide range of
impact on the elderly. The major threat of these brain diseases includes progressive loss of
memory, Alzheimer’s disease (AD), impairments in the movement, Parkinson’s disease
(PD) and Huntington’s disease (HD). Alzheimer’s disease (AD) is one of the utmost neurodegenerative disorders that affect the elderly. During AD accumulation of amyloid beta
protein, neuronal or synaptic loss and brain atrophy in particular areas of the brain occurs.
AD affects the neocortex as well as the hippocampus; brain plaques and tangles are the
key characteristics of AD. An imbalance between the oxidant-antioxidant systems could
determine the degree of cellular damage. Oxidative stress and mitochondrial dysfunction
are key hallmark features of neurodegeneration [117], and plays an important role in the
progression of neuronal damage during AD [118]. This ROS-mediated neuronal damage
occurs due to the disruption of redox reaction, i.e., decrease in the activities of antioxidant
enzymes such as superoxide dismutase and catalase activities, and a decrease in the level
of antioxidants (ascorbic acid and tocopherol) favors the surplus ROS production along
with increased accumulation of Aβ in AD patients [119]. Aβ plaques are deposited in the
extracellular region of the endoplasmic reticulum and Golgi apparatus. This increase in the
deposition of Aβ plaques during initial stages of AD also increases oxidative stress and
finally leads to mitochondrial dysfunction [120,121]. Increased expression of amyloid mutant amyloid precursor protein and presenilin-1 increases the levels of hydrogen peroxide
(H2 O2 ) and lipid peroxidation [119,122]. It also promotes the phosphorylation of tau protein
in AD patients [119]. It has been studied that removal of cytoplasmic/zinc superoxide dismutase (SOD) drives the β-Amyloid protein oligomerization and memory Loss in a mouse
model of Alzheimer’s disease [123,124]. Previous studies reported that overexpression of
tau protein increases susceptibility of oxidative stress and reduction of peroxisomes [125].
Besides this, overexpressed mutant tau proteins (P301S and P301L) decrease the activity
of nicotinamide adenine dinucleotide hydrogen-oxidoreductase, leading to mitochondrial
dysfunction. Both factors are responsible for the ROS production [126–128]. It has been
reported this mitochondrial dysfunction inhibits the efficient generation of adenosine
triphosphate (ATP) [119,129]. Moreover, mitochondrial dysfunction in neuronal cells also
downregulates the expression of electron transport chain (ETC) genes responsible for the
activation of pyruvate, cytochrome oxidase and α-ketoglutarate dehydrogenase [130,131].
ROS-induced inactivation of antioxidant enzyme activities such as superoxide dismutase (SOD), activation of p38 and phosphorylation of tau protein causes an accumulation
of neurofibrillary tangles, which are represented in Figure 7. Moreover, the role of ROS in
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ation of adenosine triphosphate (ATP) [119,129]. Moreover, mitochondrial dysfunction in
neuronal cells also downregulates the expression of electron transport chain (ETC) genes
responsible for the activation of pyruvate, cytochrome oxidase and α-ketoglutarate dehydrogenase [130,131].
ROS-induced inactivation of antioxidant enzyme activities such as superoxide
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mutase (SOD), activation of p38 and phosphorylation of tau protein causes an accumulation of neurofibrillary tangles, which are represented in Figure 7. Moreover, the role of
ROS in activation of cdk5, the release of intracellular Ca2+ and the inhibition of the wnt
activation of cdk5, the release of intracellular Ca2+ and the inhibition of the wnt pathway
pathway are also explained in Figure 7 Due to the inactivation of the wnt pathway, GSK3β
are also explained in Figure 7 Due to the inactivation of the wnt pathway, GSK3β becomes
becomes activated and then favors the phosphorylation of tau proteins.
activated and then favors the phosphorylation of tau proteins.

Figure 7. The diagram shows the involvement of reactive oxygen species and amyloid β in
Alzheimer’s disease, where Aβ; amyloid plaques, NFT: neurofibrillary tangles; AD: Alzheimer’s
disease, SOD: superoxide dismutase, CAT: Catalase, APP: Amyloid β (Aβ) precursor protein,
GSK3β: Glycogen synthase kinase-3, Wnt-1: Wingless and Int-1, Cdk5: Cyclin-dependent kinase-5,
PRx: peroxiredoxin, RCAN1: regulator of calcineurin 1.

3.2. Parkinson’s Disease
Parkinson’s disease is a progressive nervous system disorder that affects movement.
Common symptoms include tremors, slowness of movement, stiff muscles, unsteady walk
and balance and coordination problems. Symptoms start developing slowly, occasionally
starting with a barely noticeable tremor in just one hand. Tremors are common, but the
disorder also commonly causes stiffness or slowing of movement. Various sources and
mechanism are involved in the generation of ROS viz metabolism of dopamine itself,
mitochondrial dysfunction, iron, neuro-inflammatory cells, calcium and aging. The gene
product involved in the development of PD includes DJ-1, PINK1, parkin, alpha-synuclein
and LRRK2, and also impacts mitochondrial function in complex ways, leading to the
aggravation of ROS generation and vulnerability to OS. Moreover, OS influences the cellular
homeostatic processes including ubiquitin-proteasome system and mitophagy. Interaction
among all these mechanisms contribute to neurodegeneration in PD due to OS, which
damages important cellular pathogenetic proteins that causes surplus generation of ROS.
Parkinson’s disease (PD) is distinguished by discriminating neuronal loss of dopaminergic
neurons in the substantia nigra pars compacta (SNc) and reduced dopaminergic level
in the nigrostriatal dopaminergic pathway in the brain [132,133]. It is thought that OSinduced pathophysiological condition is the fundamental cause of Parkinson’s disease
(PD) [133,134]. Recent studies reported that decreased activity of respiratory complex I in
substatia nigra pars compacta of patients suffering from Parkinson’s disease may cause
excessive ROS generation and induce cellular loss of dopaminergic neurons [133–135].

Cells 2022, 11, 552

Cells 2022, 11, x

13 of 27

The inhibitors such as 1-methyl-4-phenyl 1,2,3,4-tetrahydrpyridine (MPTP) and its
metablites, 1-methyl4-phenylpyridinium (MPP+) of Complex I may lead to the cytotoxic
effects on the dopaminergic neurons, resulting in clinical parkinsonian phenotype, and induce nigral degeneration with cytoplasmic α-synuclein [136]. Genetic mutations in proteins
such as α-synuclein, parkin, and phosphatase and tensin homolog induce putative kinase
that were associated with the ancestral forms of Parkinson’s disease [133]. The functions of
mitochondria have been affected when these genes are mutated and increases ROS-induced
oxidative stress [133]. Some studies evidenced that point mutations and deletion in the
mitochondrial DNA might cause a defect(s) in complex I or mitochondrial dysfunction
in Parkinson’s disease [137] and encode Complex I subunits in patients suffering from
PD [137–139]
Moreover, ROS-induced destruction of dopaminergic neurons is shown in Figure 8.
ROS-induced oxidative stress decreases the level of reduced glutathione (GSH) in the
substantia nigra pars compacta of PD [140]. Increased oxidative stress accelerates the
rate of lipid peroxidation, due to the degradation of membranous polyunsaturated lipids
and degradation of protein, and ROS also induced the fragmentation of DNA. All these
processes ultimately lead to the damage of dopaminergic neurons and results in lack of
coordination among the body parts. Additionally, experimental studies conducted on
animal models have reported that the levels of Fe increase in the substantia nigra pars
14 of 28
compacta, which might arise due to dysfunctional transport of Fe to the mitochondria
during Parkinson’s disease [141,142].
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one.

4. Oxidative Stress and Chronic Kidney Diseases
Kidney diseases have become a serious health concern throughout the world. Late
diagnosis is one of the major concerns. The causes for increasing levels of kidney disease
include various factors such as an increased rate of diabetes, high blood pressure, prescription of allopathic medicines, xenobiotics, etc. These factors lead to the formation of
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4. Oxidative Stress and Chronic Kidney Diseases
Kidney diseases have become a serious health concern throughout the world. Late
diagnosis is one of the major concerns. The causes for increasing levels of kidney disease include various factors such as an increased rate of diabetes, high blood pressure, prescription
of allopathic medicines, xenobiotics, etc. These factors lead to the formation of ROS and
cause oxidative stress in the renal system. Oxidative stress is one of the major progressive
threatening factors which is responsible for the increasing prevalence of chronic kidney
diseases (CKD) or end-stage renal diseases (ESRD), and may even lead to death [143,144].
It has been reported that during initial stages of CKD, the intensity of oxidative stress
becomes accelerated [145], which autonomously results in the development of ESRD [146].
This progression from CKD to ESRD has been observed in patients undergoing Hemodialysis (HD) [146,147]. Patients with ESRD on peritoneal dialysis (PD) have amplified OS
in comparison to non-dialysis uremic patients; however, it is less when compared with
patients undergoing HD [148,149]. In the kidneys, OS is responsible for progressive kidney
damage, such as lesions to the glomeruli, renal ischemia, apoptosis and cell death, intensifying the unadorned ongoing inflammatory processes. ROS-induced OS modulates various
signaling pathways, enzymes and gene expressions in the renal system.
NADPH oxidase (Nox) leads to the production of reactive ROS and contributes significantly to the progression of renal diseases. Nox encompasses seven members (Nox
1–5, DUOX1, DUOX2), and all these isoforms differ from one another on the basis of their
respective functions: Nox1, Nox3 and Nox5 produce superoxide (O2 *− ), whereas DUOX1,
DUOX2 and Nox4 mainly produce hydrogen peroxide (H2 O2 ) [150]. For the activation
of Nox1, various membrane subunits, such as p22phox, cytosolic subunits p47phox and
p67phox, are required. Nox4 is the principal isoform of NADPH in the kidneys. Nox4 plays
a significant role in redox processes involved in diabetic nephropathy, acute kidney injury,
obstructive nephropathy, hypertensive nephropathy, renal cell carcinoma and other renal
diseases by activating many signaling pathways [151]. Even though Nox4 is found in different cells viz epithelial cells, podocytes, mesangial cells, endothelial cells and fibroblasts,
it can induce cell apoptosis, inflammation and fibrogenesis [152].
As mentioned in the previous section of this paper, amongst the DNA bases, guanine
is most susceptible to oxidative stress and 8-OH-dG (8-hydroxy-20–deoxy-guanosine) is
one of the abundant oxidative products of nucleic acids [153]. This results in oxidative
damage to nucleic acids and amplifies the signal for the commencement of consequent
tumors [154]. Other indicators of OS include oxidized low-density lipoprotein, advanced
glycation end products (AGEs), 8-hydroxyde-oxyguanosine and malondialdehyde (MDA),
which increase significantly in blood and other tissues in patients suffering from chronic
kidney disease [155]. AGEs interact with cells through a receptor system for advanced
glycation end products and the receptor for advanced glycation end-products (RAGE) [156],
which in turn stimulates the mitogen-activated protein kinase transduction pathway. Such
stimulation is responsible for the translocation of the p65 subunit of nuclear factor kappa B
from the nucleus into the cytoplasm of the cell; this further stimulates second messengers
and results in a subsequent increase in pro-inflammatory enzymes, cytokines and adhesion
molecules [157–159]
ROS-Mediated Cardio Vascular and Nephropathy
Cardiovascular disease is one of the major causes of death in the entire world, not only
in the common population but also in persons suffering from chronic kidney disease (CKD).
Therefore, it may be proposed that cardiovascular diseases and chronic kidney diseases
are interrelated with one another. Moreover, the number of patients with cardiovascular
diseases and chronic kidney disease cause increased morbidity and mortality among the
all-renal dysfunction spectrum. During cardiovascular diseases and nephropathy, the
overproduction of ROS induces stress and leads to the oxidation of LDL (oxLDL) and CM;
both of these causes affect Endothelin-1, which in turn activates NADPH oxidase (Nox)
and NO and finally leads to vasoconstriction. Moreover, ROS production can also directly
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cause nephropathy, including renal microcirculation dysfunction, renal medullary ischemia,
tubular necrosis and glomerular cell damage [160–162] (Figure 9). Additionally, Figure 9
demonstrates how elevated OS causes contrast-induced nephropathy characterized by
improper renal microcirculation, tubular necrosis and glomerular damage. Figure 9 also
16 of 28
shows how oxidative stress induces the oxidation of lipids, which causes arterial stiffness,
endothelial damage and atherosclerosis.
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homeostasis [166,167].
Moreover, OS induces abnormal signaling in mitochondria [168] which leads to
changes in mitochondrial homeostasis such as modulation in the signaling of ROS and
causes age-dependent cellular damage [169–171]. Progressive generation of ROS decreases the activity of scavenger enzymes and favors situation towards a pro-oxidant status which causes aging of cells [172–174]. It has been reported that depletion of mitochondrial superoxide dismutase and catalase causes elevation in OS in mice, which lead to

Cells 2022, 11, 552

Cells 2022, 11, x

16 of 27

Moreover, OS induces abnormal signaling in mitochondria [168] which leads to
changes in mitochondrial homeostasis such as modulation in the signaling of ROS and
17 of 28
causes age-dependent cellular damage [169–171]. Progressive generation of ROS decreases
the activity of scavenger enzymes and favors situation towards a pro-oxidant status which
causes aging of cells [172–174]. It has been reported that depletion of mitochondrial superoxide dismutase
and catalase
elevationdamage
in OS intomice,
which lead
to premature
[175–179]
and accelerates
thecauses
peroxidative
membrane
lipids,
decreasesaging
fatty
and age-associated
acids
and degrades pathogenic
the proteinsconditions
(Figure 10).[175]. This increased oxidative-stress-induced
mitochondrial
dysfunction
leads to aging
cells by
the lifeDNA
span repair
of cellssystem,
due to
ROS induce
faults in replication
and of
impair
thereducing
mitochondrial
functional inefficiency
of enzymes,
proteins
and
other biomolecules
[175–179]
andofacceleraccumulation
of aged protein
and lipids
and
decrease
the replicative
capability
DNA
ates the peroxidative
[180–185]
(Figure 10).damage to membrane lipids, decreases fatty acids and degrades the
proteins (Figure 10).

10. This
Thisdiagram
diagram
represents
of reactive
oxygen
species
(ROS)
in cellular
ageing.
Figure 10.
represents
thethe
rolerole
of reactive
oxygen
species
(ROS)
in cellular
ageing.
ROSinduced
oxidative
stress-induced
damage
in DNA
(base
ROS-induced
oxidative
stress-induced
damage
in DNA
(basealteration,
alteration,fragmentation),
fragmentation), peroxidative
peroxidative
damage
damage in
in lipids,
lipids, protein
protein degradation
degradation and
and inhibition
inhibition of
of repair.
repair. All
All these
these abnormal
abnormal changes
changes in
in the
the
cells
decrease
their
working
efficiency
and
causing
their
ageing.
Were,
GSH;
Reduced
glutathione,
cells decrease their working efficiency and causing their ageing. Were, GSH; Reduced glutathione,
GSSG:
glutathione. MDA,
GSSG: Oxidized
Oxidized glutathione.
MDA, TBARS.
TBARS. Note:
Note: Dot
Dot (.)
(.) designates
designates free
free radical.
radical.

Mitochondria-Associated
Involvement
with Aging
ROS induce faultsMembranes
in replication
and impair
the mitochondrial DNA repair system, Sites
accumulation
of aged
proteinmitochondria
and lipids and
decrease
the replicative
capability
of
of close contact
between
and
the endoplasmic
reticulum
(ER) are
DNA [180–185]
(Figure 10).
known
as mitochondria-associated
membranes (MAM) or mitochondria–ER contacts
(MERCs). They contribute significantly to both cell physiology and pathology. Aging is a
Mitochondria-Associated
Membranes
Aging of cells, tissues and the entire
composite
process associated
withInvolvement
the steady with
weakening
Sitesofofanclose
contactbody
between
and the the
endoplasmic
function
organism’s
with mitochondria
age. Aging influences
individual reticulum
function of(ER)
orare
known
as
mitochondria-associated
membranes
(MAM)
or
mitochondria–ER
ganelles, including mitochondria and the endoplasmic reticulum (ER), and hencecontacts
affects
(MERCs).
They
contribute
significantly
bothwas
cellassociated
physiologywith
andoxidative
pathology.
Aging
is a
their contact
sites.
At the cellular
level, to
aging
stress,
accucompositeofprocess
associated withimpaired
the steadyproteostasis
weakening and
of cells,
tissues organelle
and the entire
funcmulation
DNA modifications,
inefficient
turnover
tion of an organism’s body with age. Aging influences the individual function of organelles,
[186].
including
mitochondriareticulum
and the endoplasmic
reticulum (ER),
their contact
The endoplasmic
(ER) and mitochondria
areand
thehence
chief affects
intracellular
organelles that are dynamically connected through temporally form of contact, called as mitochondria-associated membranes (MAMs). These contact sites are recognized due to their
unique molecular composition, which is specifically restricted to the surrounding of the
interacting membrane fragments. These molecular assemblies construct links in such a
way that they develop a unique local environment, which could increase the transfer of

Cells 2022, 11, 552

17 of 27

sites. At the cellular level, aging was associated with oxidative stress, accumulation of
DNA modifications, impaired proteostasis and inefficient organelle turnover [186].
The endoplasmic reticulum (ER) and mitochondria are the chief intracellular organelles
that are dynamically connected through temporally form of contact, called as mitochondriaassociated membranes (MAMs). These contact sites are recognized due to their unique
molecular composition, which is specifically restricted to the surrounding of the interacting
membrane fragments. These molecular assemblies construct links in such a way that
they develop a unique local environment, which could increase the transfer of cargo or
signals among the different organelles. Previous studies have reported that MAMs form
a physical platform which enables communication between the ER and mitochondria,
which is associated with lipid biosynthesis. Moreover, the proteome of the MAMs fraction
remains on target during the various age-associated disorders including Alzheimer’s disease [187,188], amyotrophic lateral sclerosis [189,190] and type 2 diabetes mellitus [191,192],
as well as in obesity [193], GM1-gangliosidosis [194] and viral infections through human
cytomegalovirus or hepatitis C virus [195,196].
Aging is considered one of the most important factors responsible for causing elevated
ER stress and mitochondrial dysfunction, as well as the diminution of ER stress. Various
studies have also reported that ER–mitochondrial contact plays important role in the
biogenesis of mitochondrial-derived compartments [197–199], and these compartments
might play vital roles in cellular adaptation to environmental stress conditions [199]. Aging
is an important factor during which stress level increases in ER, which in turn leads to
the mitochondrial dysfunction [200]. Moreover, various studies have also suggested that
there is a correlation between spatial reorganization and elevated ATP levels, oxygen
consumption, reductive power and elevated mitochondria Ca2+ uptake [201,202]. However,
uncoupling of the organelles or blocking the Ca2+ transfer decreased the metabolic response,
interpreting cells and makes them more prone to ER stress [201,203]. Subsequently, ER
stress induces premature elevation in mitochondrial metabolism that relies mainly upon
organelle coupling and the transfer of Ca2+ [201–206].
6. The Role of ROS in the Induction of DNA Damage
6.1. Role of ROS in Mediating Genotoxin-Induced Damage
Cells are exposed to endogenous as well as exogenous sources of ROS. Surplus level of
ROS impairs physiological function through the cellular damage of DNA, proteins, lipids
and other macromolecules. ROS-mediated harmful effects contribute to the progression of
deteriorating conditions in human beings including neurodegenerative disorders, cardiac
dysfunction, cancer, aging, etc. ROS induce deleterious effect on cells, and also act as
stress-induced signaling molecules in cells. It has been reported that DNA damage is due to
the increased production of intracellular ROS, and there are various sources which damage
the DNA by ROS, such as ionizing radiations, synthetic chemicals, pesticides, etc.
Genotoxicity caused due to chemotherapeutics such as doxorubicin and cisplatin
elevates the level of ROS, inhibits the antioxidant system such as antioxidants (GSH, and
ascorbic acid), enzymes responsible for the regeneration of antioxidants, SOD, CAT and
peroxidases [207,208]. The ROS causes perforation in the mitochondrial membrane and
cytochrome C gets released and initiates the apoptosis. Moreover, cytochrome C, AfAP
and Caspase 9 activate Caspase 3, which leads to the activation of PARP and finally causes
DNA fragmentation (Figure 11).
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to facilitate recognition of the impaired regions and their repair [212,213]. A specific
dangerous lesion is the DNA double-strand break (DSB), which may be mutagenic due
to chromosomal rearrangement. To reverse the DNA damage, cells produce a network of
events, known as the DNA damage response (DDR). This response includes recognition of
damaged DNA, activation of checkpoints, cell cycle arrest and, ultimately, the outcome for
repair, apoptosis and immune clearance [214,215]. The molecular components of the DSBinduced DDR have been studied broadly and broadly divided into three major groups viz.
sensors which helps in the identification of damage. The transducer helps in coordinating
the signaling and effectors, which ultimately facilitate the outcome [216–218].
ROS are well identified as mediators of DNA damage. Ionizing radiations (IR) induce
double-stranded breaks by high-energy damage to the sugar backbone of DNA, and also
through free radicals generated in cells—mostly •OH from water [22]. Chemotherapeutics
including doxorubicin and cisplatin enhances the level of ROS and play an important role
in their genotoxic effect [23,24]. It has been reported that ROS directly induce DNA damage
by oxidizing nucleoside bases (e.g., the formation of 8-oxo guanine) [25] and convert G-T
or G-A if unrepaired. The BER pathway identifies and repaired these oxidized bases [26].
Moreover, the accumulated ROS also induces lesions in mitochondrial DNA, breaks DNA
strands and also causes degeneration of mitochondrial DNA [27].
7. Conclusions
Reactive oxygen species (ROS) are generated through different endogenous and exogenous processes. Oxidative stress is due to an imbalance between the ROS production
and antioxidants defense and is progressive with ageing. Oxidative stress is also associated
with various chronic diseases and damages such as diabetes, neuro-degenerative diseases,
obesity, cardiac hypertrophy, hepatorenal damage, reproductive dysfunction, DNA damage, mitochondrial dysfunction and finally aging of cells. Biomarkers of OS might be useful
as diagnostic tool or therapeutic target. Further investigations are needed to evaluate the
efficacy of antioxidant supplements and natural polyphenolics from plant parts to combat
the pathologies caused by oxidative stress.
8. Future Perspective
Considering ROS-induced oxidative damages and diverse pathologies on different
organ systems, it can be seen that oxidative stress leads to the evolution of numerous and
diverse pathologies in the body. Further studies are required to elucidate the mechanisms
through which oxidative-stress-related signaling can contribute to the alteration of different
organs in order to devise effective preventive and curative therapeutic strategies. Various
reports have revealed that the use of antioxidants can treat many diseases; the development
of antioxidant therapies also represents a promising avenue for ROS pathology treatment.
Antioxidant therapy, such as the use of polyphenols, flavonoids, antioxidant supplements
and other nutritional compounds, together with moderate aerobic exercise, may reverse the
damage induced by oxidative stress. Therefore, the knowledge of a particular antioxidant’s
oxidative pathway associated with ROS could allow both the identification of disease
markers and the development of preventive and curative therapeutic strategies.
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